Starling Oncology, Inc.
Starling Oncology, Inc.
- Market cap
- $305.97M
Your view on STLN
Overview
What the company does, where it operates, and who runs it.
About Starling Oncology, Inc.
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
- CEO
- Not available
- Headquarters
- 18000 Studebaker Road, Suite 800, Cerritos, CA, US
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
- CEO
- Not available
- Headquarters
- 18000 Studebaker Road, Suite 800, Cerritos, CA, US
Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population.
It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Starling Oncology, Inc.. Starting points for Starling Oncology, Inc.: EPS -$0.34, beta 0.42 — an Medical - Care Facilities name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Starling Oncology, Inc.. Trailing twelve-month EPS for Starling Oncology, Inc. stands at -$0.34. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Buy
Targets, low to high
Analyst ratings
4 firms, last 12 months- Strong Buy0
- Buy4
- Hold0
- Sell0
- Strong Sell0
Earnings per share estimates
| Per share | This quarterSep 2024 | Next quarterDec 2024 | This yearYear to Dec 2024 | Next yearYear to Dec 2025 |
|---|---|---|---|---|
| Average estimate | −$0.07 | −$0.08 | −$0.36 | −$0.59 |
| Lowest estimate | −$0.07 | −$0.08 | −$0.36 | −$0.59 |
| Highest estimate | −$0.07 | −$0.08 | −$0.36 | −$0.58 |
| Number of analysts | 1 | 1 | 1 | 1 |
| A year ago | — | — | — | — |
| Growth vs a year ago | — | — | — | — |
Revenue estimates
| Total | This quarterSep 2024 | Next quarterDec 2024 | This yearYear to Dec 2024 | Next yearYear to Dec 2025 |
|---|---|---|---|---|
| Average estimate | $107.54M | $109.15M | $414.70M | $500.58M |
| Lowest estimate | $106.31M | $108.04M | $412.42M | $497.83M |
| Highest estimate | $108.74M | $111.00M | $417.59M | $504.06M |
| Number of analysts | 1 | 1 | 1 | 1 |
| A year ago | — | — | — | — |
| Growth vs a year ago | — | — | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Starling Oncology, Inc.. Starling Oncology, Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| EXE.TOExtendicare Inc. | Healthcare | TSX | $2.7B | ||
| EXETFExtendicare Inc. | Healthcare | OTC | $1.7B | ||
| FCGDFirst Colombia Gold Corp. | Healthcare | OTC | $483,789 | ||
| FCHSFirst Choice Healthcare Solutions, Inc. | Healthcare | OTC | $131,833 | ||
| FMCQFFresenius Medical Care AG & Co. KGaA | Healthcare | OTC | $14.3B | ||
| FMSFresenius Medical Care AG & Co. KGaA | Healthcare | NYSE | $11.0B | ||
| FOXOFOXO Technologies Inc. | Healthcare | OTC | $8,997 | ||
| FPCGFirst Physicians Capital Group, Inc. | Healthcare | OTC | $10.1M | ||
| FSNUFFresenius SE & Co. KGaA | Healthcare | OTC | $31.5B | ||
| FSNUYFresenius SE & Co. KGaA | Healthcare | OTC | $136.1B | ||
| GBCSSelectis Health, Inc. | Healthcare | OTC | $9.8M | ||
| GLH.AXGlobal Health Limited | Healthcare | ASX | — | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| IWMiShares Russell 2000 ETF | $76.6B in assets | 0.01% | |
| VTIVanguard Total Stock Market ETF | $689.2B in assets | 0.00% | |
| VXFVanguard Extended Market ETF | $30.2B in assets | 0.01% | |
| IWOiShares Russell 2000 Growth ETF | $13.7B in assets | 0.01% | |
| VMO.TOVanguard Global Momentum Factor ETF | $477M in assets | 0.05% | |
| VTWGVanguard Russell 2000 Growth ETF | $1.4B in assets | 0.03% | |
| RSSLGlobal X - Russell 2000 ETF | $1.4B in assets | 0.01% | |
| VHTVanguard Health Care ETF | $19.1B in assets | 0.01% | |
Largest holders first, then the funds most concentrated in STLN.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Starling Oncology, Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
About this section
U.S. Senate disclosures naming Starling Oncology, Inc.. Starling Oncology, Inc. is a $306.0M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Starling Oncology, Inc.. Coverage tracks Starling Oncology, Inc. within Medical - Care Facilities (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Starling Oncology, Inc.